AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 22 min read$OKLO

DeWitte Jacob sold $819K of OKLO (indirect holdings)

DeWitte Jacob (Co-Founder, CEO) sold 12,600 indirectly-held shares of Oklo Inc. (OKLO) at $64.99 ($0.82M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · DeWitte Jacob
Published Jun 2, 2026, 9:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$OKLO
Neutral
medium confidence
Mentioned
$OKLO
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OKLONeutralLow
01

Why it matters

Provides an updated insider ownership datapoint (shares sold, price, and post-transaction holdings) that can marginally influence sentiment but does not change fundamentals by itself.

02

Market read

Useful for monitoring insider behavior; likely limited trading impact absent additional company-specific news.

03

What to watch

Traders may over-weight single Form 4 prints; the more informative signal is whether there’s a pattern of repeated sales outside 10b5-1 or changes in total insider ownership over time.

Relevance 7/10Novelty 6/10Timing: SEC Form 4 filed today; sale occurred 2026-06-01

Background

The article is an SEC EDGAR Form 4 disclosure of an insider sale by Oklo’s co-founder/CEO under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$OKLONeutralMedium confidence
Context

Oklo co-founder/CEO DeWitte Jacob sold 12,600 shares (~$818.9K) via a pre-arranged 10b5-1 plan, updating insider ownership data.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless accompanied by other catalysts.

Evidence & confidence

The filing is a routine 10b5-1 open-market sale by an officer/director/10% owner, providing a concrete datapoint but not new operational or financial information.

Market effects

Sector

Minimal; this is company-specific insider transaction data, not a sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • issuer
    Oklo Inc.

    Subject of the Form 4 insider transaction; co-founder/CEO sold shares under a 10b5-1 plan.

  • insider
    DeWitte Jacob

    Oklo co-founder, CEO, officer/director/10% owner who executed the sale.

Read at source← All news

Related articles

AUG 9
$OKLOMed

Oklo’s Groves Research Reactor Achieves First Criticality

Oklo (NYSE: OKLO) said its Groves Isotope Test Reactor reached first criticality on private land, supported by DOE Reactor Pilot Program authorization. Los Alamos’ ZiaCore microreactor also achieved zero-power criticality. ARC Clean Technology (ARC) outlined plans for ARC-100 at INL and a term sheet for Turkey. Holtec, Entergy and Hyundai will evaluate SMR-300 projects in Gulf states.

neutronbytes.com6 min
AUG 7
$OKLOMed

Oklo Inc. Q2 2026 Earnings Call Summary

Oklo Inc. reported progress from its Q2 2026 earnings call, including first criticality at the Groves isotope facility and plans for Aurora deployments at INL and an Ohio clean energy campus. The company targeted 2028 commercial startup, expected first isotope revenue in early 2027, and raised 2026 operating cash use guidance to $120M-$150M and PP&E spend to $400M-$500M.

yahoo.com10 min
AUG 7
$OKLOMed

Oklo Stock Attempts a Turnaround, but Technical Barriers Remain as It Releases Q2 2026 Financial Results

Oklo reported Q2 2026 revenue of $1.2 million, above analysts’ ~$83,800 estimate, but posted a $0.28 per-share loss versus a ~$0.16 consensus. Net loss widened to $48.5 million from $24.7 million a year earlier. The company ended the quarter with about $3 billion in cash and marketable securities and said its Groves Isotope Test Reactor achieved first criticality.

fxleaders.com6 min
AUG 7
$OKLOMedAI 8/10

Oklo reports $1.21M Q2 revenue, $1.6B cash as Aurora milestones advance

Oklo Inc. (NYSE: OKLO) reported Q2 2026 revenue of $1.21M versus a $126,250 analyst estimate and an EPS loss of $(0.28) versus an estimated $(0.16). The company said it ended the quarter with $1.6B cash and expects 2026 operating cash flow of $120M to $150M and capex of $400M to $500M. It also advanced Aurora regulatory steps and said its Groves reactor reached first criticality.

scanx.trade7 min